

GALACTICA BIOTECH LIMITED
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

GALACTICA BIOTECH LIMITED
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

Contents

Company Information	2
Balance Sheet	3
Notes to the Financial Statements	4

GALACTICA BIOTECH LIMITED

COMPANY INFORMATION

for the financial year ended 30 April 2025

DIRECTORS

Alina Valencia
Jorge Moises Valencia Delgadillo

SECRETARY

Jorge Moises Valencia Delgadillo

REGISTERED OFFICE

Unit 3D North Point House
North Point Business Park
New Mallow Road
Co. Cork
Ireland

COMPANY NUMBER

604626

CHARTERED ACCOUNTANTS

Lizdan Business Services Limited t/a Kinore
Ground Floor
71 Baggot Street Lower
Dublin
D02 P593
Ireland

BANKERS

Bank of Ireland
Cork
T12 FP62
Ireland

GALACTICA BIOTECH LIMITED

BALANCE SHEET

As at 30 April 2025

	2025	2024
	€	€
Current assets	51	47
Creditors: amounts falling due within one year	(113,381)	(116,911)
Net current liabilities	(113,330)	(116,864)
Total assets less current liabilities	(113,330)	(116,864)
Accruals and deferred income	(1,171)	(1,014)
Net liabilities	(114,501)	(117,878)
Capital and reserves	(114,501)	(117,878)

We, as directors of Galactica Biotech Limited, state that:

- The Company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- The Company is availing itself of the exemption on the grounds that the conditions specified in s.358 are satisfied,
- The shareholders of the Company have not served a notice on the Company under s.334(1) in accordance with s.334(2),
- We acknowledge the Company's obligations under the Companies Act 2014 and to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the Company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the Company,
- The Company has relied on the specified exemption contained in s.352 Companies Act 2014 and has done so on the grounds that the Company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with s.353 Companies Act 2014.

These financial statements have been prepared in accordance with the micro companies regime.

The financial statements of Galactica Biotech Limited (registered number: 604626) were approved and authorised for issue by the Board of Directors on 23 February 2026 and were signed on its behalf by:

Alina Valencia

Alina Valencia
Director

Jorge Valencia

Jorge Moises Valencia Delgadillo
Director

GALACTICA BIOTECH LIMITED

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Galactica Biotech Limited (registered number 604626) (the Company) is a private company, limited by shares, registered in Ireland under the Companies Act 2014. The address of the registered office is Unit 3D North Point House, North Point Business Park, New Mallow Road, Co. Cork, Ireland.

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

The functional currency of Galactica Biotech Limited is considered to be Euro because that is the currency of the primary economic environment in which the Company operates.

These financial statements are separate financial statements.

Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors note that the business has net liabilities of €114,501. The Company is supported through loans from the directors. The directors have confirmed that the loan facilities will continue to be available for at least 12 months from the date of signing these financial statements and the directors will continue to support the Company. Given the current position, the directors believe that any foreseeable debts can be met for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Trade and other debtors

Trade and other debtors are initially recognised at transaction price and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

GALACTICA BIOTECH LIMITED
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS (continued)
for the financial year ended 30 April 2025

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at transaction price and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

2. Appropriation of profit and loss

	Profit and loss account
	€
At 01 May 2023	(113,683)
Loss for the financial year	(4,295)
Total comprehensive loss	(4,295)
At 30 April 2024	(117,978)
At 01 May 2024	(117,978)
Profit for the financial year	3,377
Total comprehensive income	3,377
At 30 April 2025	(114,601)